These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. N Engl J Med; 1995 May 25; 332(21):1418-24. PubMed ID: 7723799 [Abstract] [Full Text] [Related]
5. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. J Gen Intern Med; 1995 Jun 25; 10(6):321-30. PubMed ID: 7562123 [Abstract] [Full Text] [Related]
8. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Langer A, Krucoff MW, Klootwijk P, Veldkamp R, Simoons ML, Granger C, Califf RM, Armstrong PW. J Am Coll Cardiol; 1995 Jun 25; 25(7):1552-7. PubMed ID: 7759706 [Abstract] [Full Text] [Related]
10. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Singh N, Mironov D, Armstrong PW, Ross AM, Langer A. Circulation; 1996 Apr 01; 93(7):1388-95. PubMed ID: 8641028 [Abstract] [Full Text] [Related]
14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. GUSTO investigators. N Engl J Med; 1993 Sep 02; 329(10):673-82. PubMed ID: 8204123 [Abstract] [Full Text] [Related]
15. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. Holmes DR, Califf RM, Topol EJ. J Am Coll Cardiol; 1995 Jun 02; 25(7 Suppl):10S-17S. PubMed ID: 7775708 [Abstract] [Full Text] [Related]
16. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Goel V, Naylor CD. Can J Cardiol; 1992 Jun 02; 8(1):31-8. PubMed ID: 1617509 [Abstract] [Full Text] [Related]
17. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ. J Am Coll Cardiol; 1997 Jul 02; 30(1):171-9. PubMed ID: 9207639 [Abstract] [Full Text] [Related]
19. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. J Am Coll Cardiol; 1992 May 02; 19(6):1123-8. PubMed ID: 1564212 [Abstract] [Full Text] [Related]